Get started
Author

Jose S. Campos

Observed names: J.S. Campos, Jose Campos, Jose S Campos Duran, Jose S. Campos Duran
ORCID: 0000-0003-3344-7733
Observed ORCID: 0000-0003-3344-7733
OpenAlex ID: A5032223227
Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8 + T cells
2016 · Shu Wang, Jose Campos, et al. · Proceedings of the National Academy of Sciences · 231
PDF
The immunopathological landscape of human pre-TCRα deficiency: From rare to common variants
2024 · Marie Materna, Ottavia M. Delmonte, et al. · Science · 37
Challenging systemic barriers to promote the inclusion, recruitment, and retention of URM faculty in STEM
2021 · Jose S. Campos, E. John Wherry, et al. · Cell Host & Microbe · 24
PDF
Defining and targeting patterns of T cell dysfunction in inborn errors of immunity
2022 · Jose S. Campos, Sarah E. Henrickson · Frontiers in Immunology · 11
PDF
Altered Purinergic Signaling and CD8+ T Cell Dysregulation in STAT3 GOF Syndrome
2024 · Jose S Campos Duran, Samir Sayed, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 3
Expanding mechanistic insights into the pathogenesis of idiopathic CD4+ T cell lymphocytopenia
2020 · Jose S. Campos, Sarah E. Henrickson, et al. · Journal of Clinical Investigation · 3
PDF
Evaluating the reversible control of an engineered CAR T cell ON-switch.
2017 · Amy Gilbert, Stephen Santoro, et al. · Journal of Clinical Oncology · 2
Aberrant STAT signaling drives T cell dysregulation in a targetable pediatric sepsis endotype
2024 · Robert B. Lindell, Samir Sayed, et al. · medRxiv · 1
Impaired regulation by purinergic signaling axis contributes to CD8+ T cell dysregulation in STAT3 gain of function
2026 · Jose S. Campos Duran, Montana S. Knight, et al. · JCI Insight
T cell dysregulation in pediatric obesity 2266671
2026 · Ceire Hay, Samir Sayed, et al. · The Journal of Immunology
Aberrant STAT signaling and T cell dysregulation define a targetable pediatric sepsis endotype
2026 · Robert B. Lindell, Samir U. Sayed, et al. · Journal of Clinical Investigation
T cell dysregulation and remodeling in pediatric obesity and weight loss
2026 · Ceire A. Hay, Samir U. Sayed, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Defining a New Pediatric Sepsis Endotype Associated With Bystander T Cell Activation, Dysregulated STAT3 Signaling, and Poor Prognosis
2025 · R.B. Lindell, S. Sayed, et al. · American Journal of Respiratory and Critical Care Medicine
Elevated CD38 Expression and a Concomitant Reduction in NAD+ Levels Underlie CD8+ T Cell Dysfunction in STAT1 GOF
2025 · Andrea Mauracher, Samir Sayed, et al. · Journal of Human Immunity
Dysregulated T Cell Cytokine Responses Characterize a High-Risk Pediatric Sepsis Subphenotype
2025 · Sydney Sheetz, Samir Sayed, et al. · Journal of Human Immunity
37: Dysregulated Stat3 Signaling Defines a Targetable, High-mortality Subphenotype of Pediatric Sepsis
2025 · Robert Lindell, Samir Sayed, et al. · Critical Care Medicine
The impact of pediatric obesity on T cell function
2024 · Ceire Hay, Samir Sayed, et al. · The Journal of Immunology
A Prognostic Proteomic Signature of Immune Dysregulation Is Present at Onset of Multiple Organ Dysfunction Syndrome in Pediatric Patients With and Without Sepsis
2024 · R.B. Lindell, S. Sayed, et al.
Primary Immune Regulatory Disorders (PIRDs) That Amplify mTOR Signaling Share a T Cell Exhaustion-like Process
2023 · Peyton E Conrey, Jose Campos, et al. · Blood
PDF
Amplified STAT3 signaling alters expression of CD39 in STAT3 gain-of-function (STAT3 GOF) and in healthy donor CD8+T cells
2023 · Jose S Campos Duran, Samir Sayed, et al. · The Journal of Immunology
PDF
Interrogating mechanisms of CD8 T cell dysfunction in obese asthma
2022 · Ceire Hay, Samir Sayed, et al. · The Journal of Immunology
Dysregulation of CD8+ T cell function in the setting of altered cytokine signaling due to inborn errors of immunity
2022 · Jose S Campos Duran, Peyton E Conrey, et al. · The Journal of Immunology
Alterations in STAT Signaling Dysregulate CD8 T Cell Activation
2021 · Jose Campos, Peyton Conrey, et al. · Journal of Allergy and Clinical Immunology
PDF
Abstract 2322: Intratumoral treatment with a highly interferogenic TLR9 agonist reverts tumor escape from PD-1 blockade
2016 · Shu Wang, Jose Campos, et al. · Cancer Research
Works count: 24
Citation count: 312
H-index: 4
I10-index: 4
Year
Topic
Type